Clinical trial · Interventional
A Study of LY317615 in Patients With Brain Tumors
A Phase II Trial of LY317615 in Patients With Recurrent High-Grade Gliomas
NCT00190723CI-TRIAL-00000574completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
1. The safety of LY317615 and any side effects that might be associated with the drug. 2. Whether LY317615, can help patients with brain tumors.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Malignant Glioma | Malignant Glioma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Enzastaurin | Drug | Enzastaurin | ALIAS |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- To establish data regarding the anti-tumor activity of LY317615 in patients with recurrent high-grade gliomas.
Secondary outcomes (1)
- measure
- To obtain preliminary information regarding the spectrum of toxicities of LY317615 administered to patients with recurrent high-grade gliomas
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * You must be at least 18 years old * You must have been diagnosed with a recurrent brain tumor by MRI or CT scan * You must be able to swallow the LY317615 tablets Exclusion Criteria: * You are a woman who is pregnant or breastfeeding * In view of your doctor, you have significant heart, liver, kidney, or psychiatric disease
References
Publications (0)
Data not yet available
No reference posted for this study.